Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study

BACKGROUND: A triple‐secured plasma‐derived von Willebrand factor (pdVWF) almost devoid of factor VIII (FVIII):WILFACTIN(®), was approved in France in 2003, and then in other countries for the treatment of patients with von Willebrand disease (VWD). OBJECTIVE: To investigate long‐term safety and eff...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thromb Haemost
Main Authors: Goudemand, Jenny, Bridey, Françoise, Claeyssens, Ségolène, Itzhar‐Baïkian, Nathalie, Harroche, Annie, Desprez, Dominique, Négrier, Claude, Chamouni, Pierre, Chambost, Hervé, Henriet, Céline, Susen, Sophie, Borel‐Derlon, Annie
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
HAEMOSTASIS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7496521/
https://ncbi.nlm.nih.gov/pubmed/32445594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.14928
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados